262 related articles for article (PubMed ID: 18574471)
21. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD.
Bukanov NO; Moreno SE; Natoli TA; Rogers KA; Smith LA; Ledbetter SR; Oumata N; Galons H; Meijer L; Ibraghimov-Beskrovnaya O
Cell Cycle; 2012 Nov; 11(21):4040-6. PubMed ID: 23032260
[TBL] [Abstract][Full Text] [Related]
22. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.
Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P
Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315
[TBL] [Abstract][Full Text] [Related]
23. Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8.
Billot K; Coquil C; Villiers B; Josselin-Foll B; Desban N; Delehouzé C; Oumata N; Le Meur Y; Boletta A; Weimbs T; Grosch M; Witzgall R; Saunier S; Fischer E; Pontoglio M; Fautrel A; Mrug M; Wallace D; Tran PV; Trudel M; Bukanov N; Ibraghimov-Beskrovnaya O; Meijer L
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F57-F73. PubMed ID: 29537311
[TBL] [Abstract][Full Text] [Related]
24. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S
Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803
[TBL] [Abstract][Full Text] [Related]
25. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
26. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
29. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes.
Atanasova G; Jans R; Zhelev N; Mitev V; Poumay Y
Biochem Pharmacol; 2005 Sep; 70(6):824-36. PubMed ID: 16011834
[TBL] [Abstract][Full Text] [Related]
30. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Raje N; Kumar S; Hideshima T; Roccaro A; Ishitsuka K; Yasui H; Shiraishi N; Chauhan D; Munshi NC; Green SR; Anderson KC
Blood; 2005 Aug; 106(3):1042-7. PubMed ID: 15827128
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E
Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796
[TBL] [Abstract][Full Text] [Related]
32. Seliciclib in malignancies.
Aldoss IT; Tashi T; Ganti AK
Expert Opin Investig Drugs; 2009 Dec; 18(12):1957-65. PubMed ID: 19938906
[TBL] [Abstract][Full Text] [Related]
33. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Mihara M; Shintani S; Kiyota A; Matsumura T; Wong DT
Int J Oncol; 2002 Jul; 21(1):95-101. PubMed ID: 12063555
[TBL] [Abstract][Full Text] [Related]
34. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1.
Oumata N; Bettayeb K; Ferandin Y; Demange L; Lopez-Giral A; Goddard ML; Myrianthopoulos V; Mikros E; Flajolet M; Greengard P; Meijer L; Galons H
J Med Chem; 2008 Sep; 51(17):5229-42. PubMed ID: 18698753
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological Inhibition of Cyclin-Dependent Kinases Triggers Anti-Fibrotic Effects in Hepatic Stellate Cells In Vitro.
Hübbers A; Hennings J; Lambertz D; Haas U; Trautwein C; Nevzorova YA; Sonntag R; Liedtke C
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32380742
[TBL] [Abstract][Full Text] [Related]
36. Systemic Administration of the Cyclin-Dependent Kinase Inhibitor (S)-CR8 Selectively Reduces Escalated Ethanol Intake in Dependent Rats.
Goulding SP; de Guglielmo G; Carrette LLG; George O; Contet C
Alcohol Clin Exp Res; 2019 Oct; 43(10):2079-2089. PubMed ID: 31403700
[TBL] [Abstract][Full Text] [Related]
37. [Caspase-3 plays a required role in PC12 cell apoptotic death induced by roscovitine].
Gao JX; Zhou YQ; Zhang RH; Ma XL; Liu KJ
Sheng Li Xue Bao; 2005 Dec; 57(6):755-60. PubMed ID: 16344902
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
McClue SJ; Blake D; Clarke R; Cowan A; Cummings L; Fischer PM; MacKenzie M; Melville J; Stewart K; Wang S; Zhelev N; Zheleva D; Lane DP
Int J Cancer; 2002 Dec; 102(5):463-8. PubMed ID: 12432547
[TBL] [Abstract][Full Text] [Related]
39. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse.
Nutley BP; Raynaud FI; Wilson SC; Fischer PM; Hayes A; Goddard PM; McClue SJ; Jarman M; Lane DP; Workman P
Mol Cancer Ther; 2005 Jan; 4(1):125-39. PubMed ID: 15657360
[TBL] [Abstract][Full Text] [Related]
40. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
